A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany
Purpose We assessed the occurrence of neutropenia and febrile neutropenia (FN) and the associated healthcare resource in cancer patients receiving myelosuppressive chemotherapy in combination with pegfilgrastim versus lipegfilgrastim. Methods This is a retrospective analysis using a German health in...
Gespeichert in:
| Veröffentlicht in: | Supportive care in cancer 2022-11, Vol.30 (11), p.9317-9327 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9327 |
|---|---|
| container_issue | 11 |
| container_start_page | 9317 |
| container_title | Supportive care in cancer |
| container_volume | 30 |
| creator | Link, Hartmut Thompson, Stephen F. Tian, Marc Haas, Jennifer S. Meise, Dominic Maas, Christopher Dimitrov, Stamen |
| description | Purpose
We assessed the occurrence of neutropenia and febrile neutropenia (FN) and the associated healthcare resource in cancer patients receiving myelosuppressive chemotherapy in combination with pegfilgrastim versus lipegfilgrastim.
Methods
This is a retrospective analysis using a German health insurance claims database. Adults receiving chemotherapy with a prescription code for pegfilgrastim (
n
= 734) or lipegfilgrastim (
n
= 346) were observed over a 1-year follow-up period. Patient subgroups were analyzed according to cancer type and FN risk. FN risk was based on the chemotherapy regimen and any additional neutropenia risk factors. Outcomes were adjusted via regression analysis.
Results
Most patients were classified as high FN risk (70.0% pegfilgrastim; 65.6% lipegfilgrastim cohort). The mean age was 58.2 years in the pegfilgrastim cohort and 58.0 years in the lipegfilgrastim cohort, with more female patients than male patients (77.3% vs 79.8%, respectively), and the majority had breast cancer (64.9% and 68.8%, respectively). Overall, 10.0% and 10.4% of patients receiving pegfilgrastim or lipegfilgrastim experienced a neutropenia event (
p
= 0.82), with 4.4% and 3.5% of patients experiencing a FN event (
p
= 0.49). The mean neutropenia event-related healthcare costs were €604 and €441 for the pegfilgrastim and lipegfilgrastim cohorts; among patients with lymphoma, these costs were significantly greater (
p
= 0.03) with pegfilgrastim (€1,612) versus lipegfilgrastim (€382). The mean all-cause hospitalizations were significantly (
p
|
| doi_str_mv | 10.1007/s00520-022-07353-3 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2712845962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A725052725</galeid><sourcerecordid>A725052725</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-dd883f3e1cc8100869730e3044db1b4be615f02185016fc29a9f9adec60952763</originalsourceid><addsrcrecordid>eNp9ks1q3TAQhU1pobdpXiArQTddxKl-LP8sL6FNC4FumrWYK499FWzJ1cgpeac8ZHVzU0JKKQIJZr5zGEanKM4EvxCcN5-Icy15yaUseaO0KtWrYiMqpcpGqe51seFdJcpKaf22eEd0y7loGi03xcOW2TAvECG5O2RAhEQz-sTCwDyuKYYFvQOGd7lI52yPMKW9hYgsIoU1WmQr4TkD32crSsRgDn5kFrzFyJZsfFCyFBES9uyXS3s2uQXHwU1jBEpufprhT_dlz3l2hXEGf_--eDPARHj69J4UN18-_7j8Wl5_v_p2ub0ubSW6VPZ926pBobC2zdtp665RHBWvqn4ndtUOa6EHLkWruagHKzvohg56tDXvtGxqdVJ8PPouMfxckZKZHVmcJvAYVjKyEbKtdFfLjH74C73NO_F5ukwpUYu6FfqZGmFC4_wQUgR7MDXbRur8d_nO1MU_qHx6nJ0NHvNS8KVAHgU2BqKIg1mimyHeG8HNIRfmmAuTc2Eec2FUFqmjiDLsR4zPE_9H9RsGdbzI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2731616815</pqid></control><display><type>article</type><title>A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany</title><source>SpringerLink Journals - AutoHoldings</source><creator>Link, Hartmut ; Thompson, Stephen F. ; Tian, Marc ; Haas, Jennifer S. ; Meise, Dominic ; Maas, Christopher ; Dimitrov, Stamen</creator><creatorcontrib>Link, Hartmut ; Thompson, Stephen F. ; Tian, Marc ; Haas, Jennifer S. ; Meise, Dominic ; Maas, Christopher ; Dimitrov, Stamen</creatorcontrib><description>Purpose
We assessed the occurrence of neutropenia and febrile neutropenia (FN) and the associated healthcare resource in cancer patients receiving myelosuppressive chemotherapy in combination with pegfilgrastim versus lipegfilgrastim.
Methods
This is a retrospective analysis using a German health insurance claims database. Adults receiving chemotherapy with a prescription code for pegfilgrastim (
n
= 734) or lipegfilgrastim (
n
= 346) were observed over a 1-year follow-up period. Patient subgroups were analyzed according to cancer type and FN risk. FN risk was based on the chemotherapy regimen and any additional neutropenia risk factors. Outcomes were adjusted via regression analysis.
Results
Most patients were classified as high FN risk (70.0% pegfilgrastim; 65.6% lipegfilgrastim cohort). The mean age was 58.2 years in the pegfilgrastim cohort and 58.0 years in the lipegfilgrastim cohort, with more female patients than male patients (77.3% vs 79.8%, respectively), and the majority had breast cancer (64.9% and 68.8%, respectively). Overall, 10.0% and 10.4% of patients receiving pegfilgrastim or lipegfilgrastim experienced a neutropenia event (
p
= 0.82), with 4.4% and 3.5% of patients experiencing a FN event (
p
= 0.49). The mean neutropenia event-related healthcare costs were €604 and €441 for the pegfilgrastim and lipegfilgrastim cohorts; among patients with lymphoma, these costs were significantly greater (
p
= 0.03) with pegfilgrastim (€1,612) versus lipegfilgrastim (€382). The mean all-cause hospitalizations were significantly (
p
< 0.01) higher for lymphoma patients receiving pegfilgrastim (2.76) versus lipegfilgrastim (1.60).
Conclusion
Overall, patients treated with pegfilgrastim and lipegfilgrastim were comparable in terms of neutropenia occurrences in the 1-year follow-up. In patients with lymphoma, neutropenia event-related healthcare costs and all-cause hospitalizations were significantly higher with pegfilgrastim compared with lipegfilgrastim in this study; however, this should be interpreted with caution in light of the limited sample size and the absence of clinical information.</description><identifier>ISSN: 0941-4355</identifier><identifier>EISSN: 1433-7339</identifier><identifier>DOI: 10.1007/s00520-022-07353-3</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Breast cancer ; Cancer ; Cancer patients ; Chemotherapy ; Comparative analysis ; Health aspects ; Health insurance industry ; Health services utilization ; Lymphoma ; Lymphomas ; Medical care, Cost of ; Medicine ; Medicine & Public Health ; Neutropenia ; Nursing ; Nursing Research ; Oncology ; Original Article ; Pain Medicine ; Rehabilitation Medicine ; Risk factors ; Side effects ; Women</subject><ispartof>Supportive care in cancer, 2022-11, Vol.30 (11), p.9317-9327</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>COPYRIGHT 2022 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-dd883f3e1cc8100869730e3044db1b4be615f02185016fc29a9f9adec60952763</citedby><cites>FETCH-LOGICAL-c419t-dd883f3e1cc8100869730e3044db1b4be615f02185016fc29a9f9adec60952763</cites><orcidid>0000-0002-9659-0265</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00520-022-07353-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00520-022-07353-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Link, Hartmut</creatorcontrib><creatorcontrib>Thompson, Stephen F.</creatorcontrib><creatorcontrib>Tian, Marc</creatorcontrib><creatorcontrib>Haas, Jennifer S.</creatorcontrib><creatorcontrib>Meise, Dominic</creatorcontrib><creatorcontrib>Maas, Christopher</creatorcontrib><creatorcontrib>Dimitrov, Stamen</creatorcontrib><title>A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany</title><title>Supportive care in cancer</title><addtitle>Support Care Cancer</addtitle><description>Purpose
We assessed the occurrence of neutropenia and febrile neutropenia (FN) and the associated healthcare resource in cancer patients receiving myelosuppressive chemotherapy in combination with pegfilgrastim versus lipegfilgrastim.
Methods
This is a retrospective analysis using a German health insurance claims database. Adults receiving chemotherapy with a prescription code for pegfilgrastim (
n
= 734) or lipegfilgrastim (
n
= 346) were observed over a 1-year follow-up period. Patient subgroups were analyzed according to cancer type and FN risk. FN risk was based on the chemotherapy regimen and any additional neutropenia risk factors. Outcomes were adjusted via regression analysis.
Results
Most patients were classified as high FN risk (70.0% pegfilgrastim; 65.6% lipegfilgrastim cohort). The mean age was 58.2 years in the pegfilgrastim cohort and 58.0 years in the lipegfilgrastim cohort, with more female patients than male patients (77.3% vs 79.8%, respectively), and the majority had breast cancer (64.9% and 68.8%, respectively). Overall, 10.0% and 10.4% of patients receiving pegfilgrastim or lipegfilgrastim experienced a neutropenia event (
p
= 0.82), with 4.4% and 3.5% of patients experiencing a FN event (
p
= 0.49). The mean neutropenia event-related healthcare costs were €604 and €441 for the pegfilgrastim and lipegfilgrastim cohorts; among patients with lymphoma, these costs were significantly greater (
p
= 0.03) with pegfilgrastim (€1,612) versus lipegfilgrastim (€382). The mean all-cause hospitalizations were significantly (
p
< 0.01) higher for lymphoma patients receiving pegfilgrastim (2.76) versus lipegfilgrastim (1.60).
Conclusion
Overall, patients treated with pegfilgrastim and lipegfilgrastim were comparable in terms of neutropenia occurrences in the 1-year follow-up. In patients with lymphoma, neutropenia event-related healthcare costs and all-cause hospitalizations were significantly higher with pegfilgrastim compared with lipegfilgrastim in this study; however, this should be interpreted with caution in light of the limited sample size and the absence of clinical information.</description><subject>Breast cancer</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Chemotherapy</subject><subject>Comparative analysis</subject><subject>Health aspects</subject><subject>Health insurance industry</subject><subject>Health services utilization</subject><subject>Lymphoma</subject><subject>Lymphomas</subject><subject>Medical care, Cost of</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neutropenia</subject><subject>Nursing</subject><subject>Nursing Research</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pain Medicine</subject><subject>Rehabilitation Medicine</subject><subject>Risk factors</subject><subject>Side effects</subject><subject>Women</subject><issn>0941-4355</issn><issn>1433-7339</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9ks1q3TAQhU1pobdpXiArQTddxKl-LP8sL6FNC4FumrWYK499FWzJ1cgpeac8ZHVzU0JKKQIJZr5zGEanKM4EvxCcN5-Icy15yaUseaO0KtWrYiMqpcpGqe51seFdJcpKaf22eEd0y7loGi03xcOW2TAvECG5O2RAhEQz-sTCwDyuKYYFvQOGd7lI52yPMKW9hYgsIoU1WmQr4TkD32crSsRgDn5kFrzFyJZsfFCyFBES9uyXS3s2uQXHwU1jBEpufprhT_dlz3l2hXEGf_--eDPARHj69J4UN18-_7j8Wl5_v_p2ub0ubSW6VPZ926pBobC2zdtp665RHBWvqn4ndtUOa6EHLkWruagHKzvohg56tDXvtGxqdVJ8PPouMfxckZKZHVmcJvAYVjKyEbKtdFfLjH74C73NO_F5ukwpUYu6FfqZGmFC4_wQUgR7MDXbRur8d_nO1MU_qHx6nJ0NHvNS8KVAHgU2BqKIg1mimyHeG8HNIRfmmAuTc2Eec2FUFqmjiDLsR4zPE_9H9RsGdbzI</recordid><startdate>20221101</startdate><enddate>20221101</enddate><creator>Link, Hartmut</creator><creator>Thompson, Stephen F.</creator><creator>Tian, Marc</creator><creator>Haas, Jennifer S.</creator><creator>Meise, Dominic</creator><creator>Maas, Christopher</creator><creator>Dimitrov, Stamen</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2R</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9659-0265</orcidid></search><sort><creationdate>20221101</creationdate><title>A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany</title><author>Link, Hartmut ; Thompson, Stephen F. ; Tian, Marc ; Haas, Jennifer S. ; Meise, Dominic ; Maas, Christopher ; Dimitrov, Stamen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-dd883f3e1cc8100869730e3044db1b4be615f02185016fc29a9f9adec60952763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Breast cancer</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Chemotherapy</topic><topic>Comparative analysis</topic><topic>Health aspects</topic><topic>Health insurance industry</topic><topic>Health services utilization</topic><topic>Lymphoma</topic><topic>Lymphomas</topic><topic>Medical care, Cost of</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neutropenia</topic><topic>Nursing</topic><topic>Nursing Research</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pain Medicine</topic><topic>Rehabilitation Medicine</topic><topic>Risk factors</topic><topic>Side effects</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Link, Hartmut</creatorcontrib><creatorcontrib>Thompson, Stephen F.</creatorcontrib><creatorcontrib>Tian, Marc</creatorcontrib><creatorcontrib>Haas, Jennifer S.</creatorcontrib><creatorcontrib>Meise, Dominic</creatorcontrib><creatorcontrib>Maas, Christopher</creatorcontrib><creatorcontrib>Dimitrov, Stamen</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Social Science Database</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Supportive care in cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Link, Hartmut</au><au>Thompson, Stephen F.</au><au>Tian, Marc</au><au>Haas, Jennifer S.</au><au>Meise, Dominic</au><au>Maas, Christopher</au><au>Dimitrov, Stamen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany</atitle><jtitle>Supportive care in cancer</jtitle><stitle>Support Care Cancer</stitle><date>2022-11-01</date><risdate>2022</risdate><volume>30</volume><issue>11</issue><spage>9317</spage><epage>9327</epage><pages>9317-9327</pages><issn>0941-4355</issn><eissn>1433-7339</eissn><abstract>Purpose
We assessed the occurrence of neutropenia and febrile neutropenia (FN) and the associated healthcare resource in cancer patients receiving myelosuppressive chemotherapy in combination with pegfilgrastim versus lipegfilgrastim.
Methods
This is a retrospective analysis using a German health insurance claims database. Adults receiving chemotherapy with a prescription code for pegfilgrastim (
n
= 734) or lipegfilgrastim (
n
= 346) were observed over a 1-year follow-up period. Patient subgroups were analyzed according to cancer type and FN risk. FN risk was based on the chemotherapy regimen and any additional neutropenia risk factors. Outcomes were adjusted via regression analysis.
Results
Most patients were classified as high FN risk (70.0% pegfilgrastim; 65.6% lipegfilgrastim cohort). The mean age was 58.2 years in the pegfilgrastim cohort and 58.0 years in the lipegfilgrastim cohort, with more female patients than male patients (77.3% vs 79.8%, respectively), and the majority had breast cancer (64.9% and 68.8%, respectively). Overall, 10.0% and 10.4% of patients receiving pegfilgrastim or lipegfilgrastim experienced a neutropenia event (
p
= 0.82), with 4.4% and 3.5% of patients experiencing a FN event (
p
= 0.49). The mean neutropenia event-related healthcare costs were €604 and €441 for the pegfilgrastim and lipegfilgrastim cohorts; among patients with lymphoma, these costs were significantly greater (
p
= 0.03) with pegfilgrastim (€1,612) versus lipegfilgrastim (€382). The mean all-cause hospitalizations were significantly (
p
< 0.01) higher for lymphoma patients receiving pegfilgrastim (2.76) versus lipegfilgrastim (1.60).
Conclusion
Overall, patients treated with pegfilgrastim and lipegfilgrastim were comparable in terms of neutropenia occurrences in the 1-year follow-up. In patients with lymphoma, neutropenia event-related healthcare costs and all-cause hospitalizations were significantly higher with pegfilgrastim compared with lipegfilgrastim in this study; however, this should be interpreted with caution in light of the limited sample size and the absence of clinical information.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00520-022-07353-3</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-9659-0265</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-4355 |
| ispartof | Supportive care in cancer, 2022-11, Vol.30 (11), p.9317-9327 |
| issn | 0941-4355 1433-7339 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2712845962 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Breast cancer Cancer Cancer patients Chemotherapy Comparative analysis Health aspects Health insurance industry Health services utilization Lymphoma Lymphomas Medical care, Cost of Medicine Medicine & Public Health Neutropenia Nursing Nursing Research Oncology Original Article Pain Medicine Rehabilitation Medicine Risk factors Side effects Women |
| title | A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A14%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20comparative%20assessment%20of%20neutropenia%20events,%20healthcare%20resource%20use,%20and%20costs%20among%20cancer%20patients%20treated%20with%20lipegfilgrastim%20compared%20with%20pegfilgrastim%20in%20Germany&rft.jtitle=Supportive%20care%20in%20cancer&rft.au=Link,%20Hartmut&rft.date=2022-11-01&rft.volume=30&rft.issue=11&rft.spage=9317&rft.epage=9327&rft.pages=9317-9327&rft.issn=0941-4355&rft.eissn=1433-7339&rft_id=info:doi/10.1007/s00520-022-07353-3&rft_dat=%3Cgale_proqu%3EA725052725%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2731616815&rft_id=info:pmid/&rft_galeid=A725052725&rfr_iscdi=true |